Aurobindo Pharma Ltd said on Thursday it would make and sell U.S.-based COVAXX's COVID-19 vaccine candidate for supply in India and to the United Nations Children's Fund (UNICEF) under a licensing deal.The Indian drugmaker also has non-exclusive rights to sell the shot — which is currently undergoing an early-stage trial — in certain other emerging markets, the Hyderabad-based company said in an exchange filing.Also Read | Inside the farmer disquiet at Delhi’s doorstepCOVAXX, a unit of privately-owned United Biomedical Inc, plans to pursue mid- and late-stage trials for the vaccine candidate from early 2021 in Asia, Latin America and the United States.The companies said the shot uses normal refrigeration as opposed to the freezing.